CRISPR Therapeutics CRSP EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's EBITDA margin?
- CRISPR Therapeutics (CRSP) reported EBITDA margin of -15,289.6% in Q1 2026.
- How has CRISPR Therapeutics's EBITDA margin changed year-over-year?
- CRISPR Therapeutics's EBITDA margin decreased by 1165.3% year-over-year, from -1,208.3% to -15,289.6%.
- What is the long-term trend for CRISPR Therapeutics's EBITDA margin?
- Over 3 years (2020 to 2025), CRISPR Therapeutics's EBITDA margin has grown at a -27.4% compound annual growth rate (CAGR), from -48,018.2% to -18,378.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.